Predictive Oncology Inc. (NASDAQ: POAI) Appoints New Board Member, Audit Committee Chair
- New board member, audit committee chair brings 35 years of accounting experience, mainly in management
- Prior worked as CFO, controller in several genomics, health companies
- POAI to leverage Prior’s new insights, guidance in the financial space
Predictive Oncology Inc. (NASDAQ: POAI), a leader in the cancer precision-medicine field, announced that Pam Prior, CPA, has been appointed to the company’s Board of Directors. In addition to holding a seat on the board, Prior will also chair the company’s audit committee.
Prior, 57, joins POAI’s Board of Directors with 35 years of experience in accounting, mainly in management as CFO or controller. As the founder and CEO of Priorities Group Inc., a provider of CFO services to small and mid-sized businesses, she has served as a CFO to a number of companies, including Gentris Corp., a private pharmacogenomics company subsequently purchased by Cancer Genetics Inc. Most recently, Prior was CFO at Schiller Grounds Care, a privately held lawn and garden equipment manufacturer.
Other previous CFO experience includes working with companies in the health-industry space such as Global Specimen Solutions, a privately held technology company for specimen and consent management (later purchased by Covance), and multimillion-dollar companies in other industries such as Greatwide Truckload Management, a $300 million subsidiary of a $1 billion privately held logistics company.
“Predictive Oncology is very fortunate to announce that Pam Prior is joining our Board of Directors,” Predictive Oncology CEO Dr. Carl Schwartz stated in a news release (http://nnw.fm/Xiep6). “Pam possesses a strong financial background, including in the genomic and health industry fields. She will chair our audit committee, providing new insights and guidance to our Board and the financial departments of the company. I greatly anticipate working with Pam and experiencing the successful approach she has honed over the years.”
In addition to her background in the health industry, Prior also has experience serving as controller for several publicly traded companies and their subsidiaries, including Tasty Baking Company and PCI Services, a part of publicly held Cardinal Health.
Prior is a licensed CPA in the Commonwealth of Pennsylvania, with an MBA and a bachelor’s degree from the University of Delaware. She also serves as treasurer on the boards of two nonprofit organizations: The Crossing Choir, a professional choir holding two Grammy Awards and seven Grammy nominations, and A Soldier’s Hands, a grassroots organization dedicated to delivering care packages to deployed United States military personnel.
As a highly respected and seasoned finance executive with valuable genomics and health industry experience, Prior joins POAI at a time when the company has announced a significant milestone in its CancerQuest 2020 initiative. The initiative indicates a progression in its proprietary AI-driven predictive model of ovarian cancer, which it expects to commercialize in the first quarter of 2020.
Prior’s engagement in providing new insights and guidance to the board and POAI’s financial departments will position the company to capitalize on its cutting-edge technology that offers an unparalleled predictive tool for pharmaceutical companies and medical researchers, enabling more effective development of new drugs and supporting clinicians in creating individualized therapies for their patients.
POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (PDx) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow.
For more information, visit the company’s website at www.Predictive-Oncology.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- New board member, audit committee chair brings 35 years of accounting experience, mainly in management
- Prior worked as CFO, controller in several genomics, health companies
- POAI to leverage Prior’s new insights, guidance in the financial space
Predictive Oncology Inc. (NASDAQ: POAI), a leader in the cancer precision-medicine field, announced that Pam Prior, CPA, has been appointed to the company’s Board of Directors. In addition to holding a seat on the board, Prior will also chair the company’s audit committee.
Prior, 57, joins POAI’s Board of Directors with 35 years of experience in accounting, mainly in management as CFO or controller. As the founder and CEO of Priorities Group Inc., a provider of CFO services to small and mid-sized businesses, she has served as a CFO to a number of companies, including Gentris Corp., a private pharmacogenomics company subsequently purchased by Cancer Genetics Inc. Most recently, Prior was CFO at Schiller Grounds Care, a privately held lawn and garden equipment manufacturer.
Other previous CFO experience includes working with companies in the health-industry space such as Global Specimen Solutions, a privately held technology company for specimen and consent management (later purchased by Covance), and multimillion-dollar companies in other industries such as Greatwide Truckload Management, a $300 million subsidiary of a $1 billion privately held logistics company.
“Predictive Oncology is very fortunate to announce that Pam Prior is joining our Board of Directors,” Predictive Oncology CEO Dr. Carl Schwartz stated in a news release (http://nnw.fm/Xiep6). “Pam possesses a strong financial background, including in the genomic and health industry fields. She will chair our audit committee, providing new insights and guidance to our Board and the financial departments of the company. I greatly anticipate working with Pam and experiencing the successful approach she has honed over the years.”
In addition to her background in the health industry, Prior also has experience serving as controller for several publicly traded companies and their subsidiaries, including Tasty Baking Company and PCI Services, a part of publicly held Cardinal Health.
Prior is a licensed CPA in the Commonwealth of Pennsylvania, with an MBA and a bachelor’s degree from the University of Delaware. She also serves as treasurer on the boards of two nonprofit organizations: The Crossing Choir, a professional choir holding two Grammy Awards and seven Grammy nominations, and A Soldier’s Hands, a grassroots organization dedicated to delivering care packages to deployed United States military personnel.
As a highly respected and seasoned finance executive with valuable genomics and health industry experience, Prior joins POAI at a time when the company has announced a significant milestone in its CancerQuest 2020 initiative. The initiative indicates a progression in its proprietary AI-driven predictive model of ovarian cancer, which it expects to commercialize in the first quarter of 2020.
Prior’s engagement in providing new insights and guidance to the board and POAI’s financial departments will position the company to capitalize on its cutting-edge technology that offers an unparalleled predictive tool for pharmaceutical companies and medical researchers, enabling more effective development of new drugs and supporting clinicians in creating individualized therapies for their patients.
POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (PDx) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow.
For more information, visit the company’s website at www.Predictive-Oncology.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
